<DOC>
	<DOC>NCT01815450</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.</brief_summary>
	<brief_title>BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Males or females 12 to 45 years of age with facial acne vulgaris Qualifying Investigator's Global Assessment severity score Qualifying number of noninflammatory lesions Qualifying number of inflammatory lesions Facial hair (beard), excessive scarring, sunburn or other disfigurement that may obscure the accurate assessment of acne grade Using medications that are reported to exacerbate acne Any clinically relevant finding at their baseline physical examination or dermatological medical history such as severe systemic diseases or diseases of the facial skin Have a known hypersensitivity or previous allergic reaction to any of the components Patients who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>